Document Detail

Interventions in acute myocardial infarction.
MedLine Citation:
PMID:  2407374     Owner:  NLM     Status:  MEDLINE    
Results of multiple studies have amply verified the benefit of urgent coronary revascularization for patients who have acute myocardial infarction (MI). Currently, intravenous thrombolytic therapy is the treatment of choice for many patients, especially those 75 years old or younger who present within 6 hours of symptom onset and who are without contraindications to thrombolytic therapy. Some patients treated within 6-24 hours of symptom onset may also benefit, but this remains unproven. The thrombolytic agents currently in use or being extensively evaluated include streptokinase, urokinase, tissue-type plasminogen activator (t-PA), anisoylated plasminogen streptokinase activator complex (APSAC or anistreplase), and single-chain urokinase-type plasminogen activator (scu-PA). The agent t-PA has the potential advantage of being clot selective and, thereby, relatively fibrinogen sparing, and its efficacy in terms of restoration of vessel patency is less dependent on the time of administration as compared with that of streptokinase and urokinase. It is not yet known whether this will translate into improved patient survival as compared with that achieved by the less-expensive agents streptokinase and APSAC. Treatment regimens of combination thrombolytic agents have been developed, but the optimal combinations have not yet been determined. Patients who are in cardiogenic shock and those in whom thrombolytic therapy is contraindicated can probably benefit from angioplasty or bypass surgery. Results of several studies have suggested that immediate angioplasty after successful thrombolysis is not beneficial; however, the potential benefit of angioplasty or bypass surgery for failed thrombolytic therapy is yet to be evaluated. Although many advances have been made, further research is clearly needed in the area of reperfusion.
S G Ellis
Related Documents :
1098684 - Procainamide and phenytoin. comparative study of their antiarrhythmic effects at appare...
1557004 - Thrombolytic therapy.
10639264 - Invasive strategies to achieve infarct-related artery patency.
10856384 - Degree of residual stenosis in the culprit coronary artery after thrombolytic administr...
6696134 - Transmural ph gradient in canine myocardial ischemia.
24509284 - Rapid endovascular catheter core cooling combined with cold saline as an adjunct to per...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Circulation     Volume:  81     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1990 Mar 
Date Detail:
Created Date:  1990-04-06     Completed Date:  1990-04-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  IV43-50     Citation Subset:  AIM; IM    
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Artery Bypass
Drug Combinations
Evaluation Studies as Topic
Fibrinolytic Agents / adverse effects,  therapeutic use
Myocardial Infarction / physiopathology,  therapy*
Myocardial Reperfusion / standards
Postoperative Care
Time Factors
Reg. No./Substance:
0/Drug Combinations; 0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitative and qualitative ST segment monitoring during and after percutaneous transluminal corona...
Next Document:  Myocardial reperfusion injury. Histopathological effects of perfluorochemical.